Daniel Higazi
Vice President, Biologics Pharmaceutical Development, CMC Ipsen Pharma
Dan joined Ipsen in 2016 where he now leads Biologics Pharmaceutical Development, who are responsible for designing our Neurotoxin and Biological medicines, including all elements of the product & biomanufacturing process to provide investigational medicines to patients at all phases of Development
Dan has 20 years experience in biopharmaceutical R&D supporting many successful medicine development programs for therapeutic proteins, with broad experience across different Biological product modalities, formerly working at AstraZeneca (MedImmune), Eisai Pharmaceuticals and small biotechs.
Dan’s responsibilities and interests span from protein engineering (developability by design) to biomanufacturing process design, to analytics and formulation development, where he has patented, published and presented widely.
Seminars
Identifying, selecting and maintaining strong relationships with external manufacturing partners is vital to navigate the complex global ADC supply chain, often with multiple CMO partners whilst under accelerated ADC development timelines
Join this strategy-led workshop to navigate selection criteria and best practices to ensure beneficial relationships with outsourcing partners and de-risk your ADC manufacturing and supply
Workshop highlights include:
- Discussing opportunities to establish and maintain effective collaboration between sponsor companies and CMOs
- Breaking down criteria considerations to assess and prioritise manufacturing partner selection
- Assessing challenges in ADC drug-linker manufacturing and supply to understand key risk factors and deploy best strategies for mitigation management
